論文・技術情報追加のお知らせ

1. Adverse Events Associated with Clascoterone: A Real-World Pharmacovigilance Study of the Food and Drug Administration Adverse Event Reporting System.

ニキビ治療薬クラスコテロンの安全性をFAERSで解析。

対象DB：FAERS

2. Hepatotoxicity Associated with Labetalol Use: A Case Report with Systematic Review and Disproportionality Analysis Using FAERS.

ラベタロール関連肝毒性の症例報告、系統的レビュー、不均衡解析。

対象DB：FAERS

3. Adverse Events Reported with Standard-Dose and High-Dose Aflibercept: A FAERS Pharmacovigilance Study.

アフリベルセプトの通常量と高用量での副作用をFAERSで比較。

対象DB：FAERS

4. Real-world pharmacovigilance analysis of pralatrexate using the FDA adverse event reporting system database.

プララトレキサートの副作用をFAERSデータに基づき解析。

対象DB：FAERS

5. Interleukin-17 Inhibitors and the Potential Association of Systemic Lupus Erythematosus.

IL-17阻害薬と全身性エリテマトーデス発症の潜在的関連。

対象DB：FAERS

6. Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports.

小児がんへのベネトクラク適応外使用時の好中球減少と感染症。

対象DB：FAERS

7. Safety assessment of Neulasta(R) (pegfilgrastim) in patients with solid tumors: a real-world adverse event analysis from the FAERS database.

固形がん患者におけるペグフィルグラスチムのリアルワールド解析。

対象DB：FAERS

8. Exploratory assessment of bleeding risk associated with concurrent use of Anti-VEGF agents and anticoagulants in oncology.

抗VEGF薬と抗血栓薬の併用による出血リスクの探索的評価。

対象DB：FAERS

9. Real-world pharmacovigilance of drug-induced osteoporosis: a focus on antiretroviral therapy and toxicological mechanisms in the elderly.

薬剤性骨粗鬆症のリスク解析。抗レトロウイルス薬等に注目。

対象DB：FAERS

10. ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.

ADHD治療薬の離脱症状に関するFAERSを用いた薬物監視研究。

対象DB：FAERS

11. Emerging Safety Signals of Sonidegib Hedgehog Inhibition for Basal Cell Carcinoma: A Real-World Analysis from the FDA Adverse Event Reporting System (FAERS).

基底細胞がん治療薬ソニデギブの新規安全性シグナルの特定。

対象DB：FAERS

12. From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine.

COVID-19 mRNAワクチン(モデルナ)の安全性評価の変遷。

対象DB：FAERS,VAERS

13. Exploring the Associations and Mechanisms Between Antihypertensive Drugs and Urological Tumors: Insights from a Mendelian Randomization Study.

降圧薬と泌尿器系腫瘍の関連およびメカニズムの解析。

対象DB：FAERS

14. Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database.

FAERSデータに基づき、薬剤性ケトアシドーシスを包括的に解析。

対象DB：FAERS

15. Drug-associated road traffic accidents: insights from an analysis of the FDA adverse event reporting system (FAERS) database.

FAERSから得られた薬剤関連交通事故に関する分析結果。

対象DB：FAERS

16. Adverse events signals of enzyme replacement drugs of Gaucher disease: insights from FAERS database analysis.

ゴーシェ病酵素補充療法の副作用シグナルをFAERSで解析。

対象DB：FAERS

17. Identifying High-Risk Medications for Drug-Induced Dystonia: A 20-Year Retrospective Real-World Pharmacovigilance Study Based on FAERS.

薬剤性ジストニアの高リスク薬を特定。20年間のFAERS解析。

対象DB：FAERS

18. Safety of Glyburide Use During Pregnancy: A Real-World Study Based on the FAERS Database.

妊娠中のグリブリド使用の安全性をFAERSデータに基づき解析。

対象DB：FAERS

19. Drug-induced gingival overgrowth: FAERS based real-world pharmacovigilance study and network pharmacology analysis.

薬剤性歯肉増殖のリスクをFAERSおよびネットワーク薬理学で解析。

対象DB：FAERS

20. Adverse Events Associated with Over-the-counter Antidiarrheals in Children: An Observational Real-world FAERS-based Disproportionality Analysis Study.

小児におけるOTC下痢止め薬の副作用に関する観察研究。

対象DB：FAERS

21. Calculating Glucagon-Like Pepide-1 Receptor Agonist-Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System.

GLP-1受容体作動薬による髄様甲状腺がんリスク予測モデルを提案。

対象DB：FAERS

22. Unveiling unexpected adverse events and haemorrhagic safety: post-marketing safety surveillance of ramucirumab from the FAERS database.

ラブリズマブの市販後安全性監視。予期せぬ副作用と出血の安全性。

対象DB：FAERS

23. Corneal edema: an underrecognized safety risk of amantadine.

アマンタジンによる角膜浮腫。認識不足の安全性リスクを特定。

対象DB：FAERS

24. Suicidality Reports in Acne Patients Treated With Isotretinoin and Concomitant Antidepressants: A Descriptive Analysis of FDA Adverse Event Reporting System Data.

イソトレチノインと抗うつ薬併用者の自殺傾向に関する記述的分析。

対象DB：FAERS

25. Cardiac adverse events associated with axitinib: A real-world pharmacovigilance study based on the Japanese adverse drug event report database.

アキシチニブに関連する心臓副作用をJADERに基づき解析。

対象DB：JADER

26. Iotadiosyncratic Non-Cardiogenic Pulmonary Edema Following Acetazolamide Administration: A Case Report and Review of Pathogenic Mechanisms.

アセタゾラミド投与後の特異的な非心原性肺水腫の症例報告。

対象DB：EudraVigilance

27. Methylphenidate and Psychotic Symptoms in Children and Adolescents: A Disproportionality Analysis on the WHO Safety Database (VigiBase).

小児・若年層のメチルフェニデートと精神病症状の不均衡解析。

対象DB：VigiBase

28. Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).

GLP-1作動薬の安全性比較で薬別リスク判明

対象DB：VigiBase

29. Detecting drug-related problems following metabolic and bariatric surgery using pharmacovigilance databases.

薬物監視データを用い、肥満手術後の薬剤関連問題を特定。

対象DB：VigiBase

30. Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.

2型糖尿病でのGLP-1薬による抑うつ・自殺念慮のVigiBase解析。

対象DB：VigiBase

31. Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.

多発性骨髄腫治療薬3種ベースの併用療法の副作用プロファイル比較。

対象DB：VigiBase

32. Disparity of ophthalmic surgeries in Japan.

日本における眼科手術の実施率に関する地域格差の調査。

対象DB：DPC,NDB

33. Uptrend in esotropia incidence in the era of excessive smartphone use: A nationwide population-based cohort study in Japan, 2014-2019.

スマホ過剰利用時代における内斜視発症率の増加に関する全国調査。

対象DB：NDB

34. Nationwide trends and variations in reverse shoulder arthroplasty in Japan: national database analysis 2014-2023.

日本におけるリバース型人工肩関節置換術の全国的な動向と変化。

対象DB：NDB

35. Correlation between the regional differences in rehabilitation and the lifelong learning among physical therapists: an ecological study.

理学療法士の生涯学習とリハビリテーションの地域差の相関。

対象DB：NDB

36. Association between Primary Hypercholesterolemia, Including Familial Hypercholesterolemia, and Abdominal Aortic Aneurysm in the General Population: Results of NDB-K7Ps-Study-5.

家族性高コレステロール血症等と腹部大動脈瘤の関連を調査。

対象DB：NDB

37. Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan.

NMOSD患者におけるC5阻害薬とサトラリズマブの治療継続率比較。

対象DB：MDV

38. Potential interactions between SSRIs and DOACs: population-based cohort and case-crossover study.

SSRIとDOACの潜在的相互作用に関するコホート・クロスオーバー研究。

対象DB：CPRD

39. Exploring Patient Perspectives on the Use of Artificial Intelligence to Inform Joint Decision-Making for Patients With Multiple Conditions in Primary Care in the United Kingdom: Qualitative Study.

共同意思決定を支援するAI利用に関する患者の視点の探索。

対象DB：CPRD

40. How does diagnostic subtype affect the quality of primary care for people with dementia? A retrospective cohort study in 1490 English general practices.

診断亜型が認知症患者へのプライマリケアの質に与える影響。

対象DB：CPRD

41. The incidence, mortality and complications of systemic lupus erythematosus: a population-level cohort study from 2012 to 2023.

全身性エリテマトーデスの発症率、死亡率、合併症の住民コホート。

対象DB：CPRD

42. Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims database.

日本におけるレカネマブ早期導入期の診断タイムラインの調査。

対象DB：DeSC

43. Treatment Patterns in Patients with Late-Onset Myasthenia Gravis in Japan: An Insurance Claims Database Study.

日本における晩期発症重症筋無力症患者の治療パターンの実態。

対象DB：DeSC

44. Insomnia and the Risk of Atrial Fibrillation: A Nationwide, Real-World Cohort Study.

不眠症と心房細動の発症リスクの関連。全国規模コホート研究。

対象DB：DeSC